Objective. The aim of the present analysis was to explore the efficacy of Bevacizumab (Bev) on survival out-come in advanced low grade serous ovarian cancer (LGSOC) both in first line and in recurrent setting.Methods. In retrospective observational multicenter study, we described the outcome of LGSOC patients en-rolled in the MITO 22 study and treated with chemotherapy (CT) with or without Bev. Patients receiving Bev in first-line or in recurrence were considered and compared with patients receiving CT alone (stage III and IV in first line; platinum based-CT in second line). Descriptive and survival analyses were performed for each group.Results. Out of 128 patients included in MITO 22, 46 LGSOC patients receiving Bev in first line setting or at the time of first recurrence were identified. In first line, 30 patients received Bev + CT and 65 CT alone and the median PFS were 47.86 months (95% CI: 31.48 -NR) and 22.63 months (95% CI 15-39.24) (p-value 0.0392), respectively. In the recurrent setting, 16 patients who received Bev + CT were compared to 33 women treated with platinum -based CT alone. Median PFS were 37.1 months (95% CI: 13.42-40.56) and 11.22 months (95% CI: 8.26-15.63) (p -value 0.013), respectively.Conclusions. Our study suggests that Bev might be effective in LGSOC both at diagnosis and at the time of relapse. These data warrants further studies.(c) 2023 Published by Elsevier Inc.

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial

Turinetto, Margherita;Tuninetti, Valentina;Valabrega, Giorgio;
2023-01-01

Abstract

Objective. The aim of the present analysis was to explore the efficacy of Bevacizumab (Bev) on survival out-come in advanced low grade serous ovarian cancer (LGSOC) both in first line and in recurrent setting.Methods. In retrospective observational multicenter study, we described the outcome of LGSOC patients en-rolled in the MITO 22 study and treated with chemotherapy (CT) with or without Bev. Patients receiving Bev in first-line or in recurrence were considered and compared with patients receiving CT alone (stage III and IV in first line; platinum based-CT in second line). Descriptive and survival analyses were performed for each group.Results. Out of 128 patients included in MITO 22, 46 LGSOC patients receiving Bev in first line setting or at the time of first recurrence were identified. In first line, 30 patients received Bev + CT and 65 CT alone and the median PFS were 47.86 months (95% CI: 31.48 -NR) and 22.63 months (95% CI 15-39.24) (p-value 0.0392), respectively. In the recurrent setting, 16 patients who received Bev + CT were compared to 33 women treated with platinum -based CT alone. Median PFS were 37.1 months (95% CI: 13.42-40.56) and 11.22 months (95% CI: 8.26-15.63) (p -value 0.013), respectively.Conclusions. Our study suggests that Bev might be effective in LGSOC both at diagnosis and at the time of relapse. These data warrants further studies.(c) 2023 Published by Elsevier Inc.
2023
172
72
77
https://www.sciencedirect.com/science/article/pii/S0090825823001464?via=ihub
bevacizumab, advanced low grade, serous ovarian cance, MITO 22, trial.
Musacchio, Lucia; Turinetto, Margherita; Arenare, Laura; Bartoletti, Michele; Califano, Daniela; Tuninetti, Valentina; Marchetti, Claudia; Cormio, Gennaro; Loizzi, Vera; Pisano, Carmela; Salutari, Vanda; Valabrega, Giorgio; Priolo, Domenico; Cecere, Sabrina Chiara; Ventriglia, Jole; Raspagliesi, Francesco; Perrone, Francesco; Fagotti, Anna; Lorusso, Domenica; Scambia, Giovanni; Pignata, Sandro
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0090825823001464-main.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 486.05 kB
Formato Adobe PDF
486.05 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1900232
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
social impact